Phaseline

Companies › Sinovac Biotech

Sinovac Biotech: clinical trials, targets and expected readouts

7 active drug programs in 12 registered trials: 7 Phase 3, 4 Phase 4, 1 Phase 1; Infectious disease, Vaccines; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Healive (hepatitis A vaccine (human diploid cell), inactivated)
Inactivated hepatitis A virus vaccine
–Phase 4Hepatitis A; Hepatitis A VaccineSep 2027
sIPV (Sabin Strain Inactivated Poliovirus Vaccine)
Inactivated poliovirus vaccine using Sabin strain
–Phase 4Poliomyelitis–
wIPV (Wild Strain Inactivated Poliovirus Vaccine)
Inactivated poliovirus vaccine using wild strain
–Phase 4Poliomyelitis–
Group ACYW135 Meningococcal Conjugate Vaccine
Meningococcal polysaccharide conjugate vaccine targeting serogroups A, C, Y, W135
–Phase 3Epidemic MeningitisNov 2026
bivalent enterovirus vaccine (Vero cell), inactivated
inactivated bivalent enterovirus vaccine targeting Enterovirus 71 and Coxsackievirus A16
EV71, CA16Phase 3Hand, Foot, and Mouth Disease(HFMD)Nov 2026
Sinovac QIV
Influenza vaccine (split virion), inactivated, quadrivalent
–Phase 3Influenza–
Lyophilized herpes zoster virus mRNA vaccine
mRNA vaccine encoding herpes zoster virus antigens
–Phase 1Herpes ZosterApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07354269sIPV (Sabin Strain Inactivated Poliovirus Vaccine)Phase 4PoliomyelitisInfectious diseaseApr 2026
NCT07211152Sinovac QIVPhase 3InfluenzaInfectious diseaseJun 2026
NCT07457060sIPV (Sabin Strain Inactivated Poliovirus Vaccine)Phase 4PoliomyelitisInfectious diseaseSep 2026
NCT07457060wIPV (Wild Strain Inactivated Poliovirus Vaccine)Phase 4PoliomyelitisInfectious diseaseSep 2026
NCT07505888Group ACYW135 Meningococcal Conjugate VaccinePhase 3Epidemic MeningitisVaccinesNov 2026
NCT06734832bivalent enterovirus vaccine (Vero cell), inactivatedPhase 3Hand, Foot, and Mouth Disease(HFMD)Infectious diseaseNov 2026
NCT07505836Group ACYW135 Meningococcal Conjugate VaccinePhase 3Epidemic MeningitisVaccinesJan 2027
NCT07505810Group ACYW135 Meningococcal Conjugate VaccinePhase 3Epidemic MeningitisVaccinesApr 2027
NCT07505823Group ACYW135 Meningococcal Conjugate VaccinePhase 3Epidemic MeningitisVaccinesApr 2027
NCT07400003Lyophilized herpes zoster virus mRNA vaccinePhase 1Herpes ZosterVaccinesApr 2027
NCT07793227Healive (hepatitis A vaccine (human diploid cell), inactivated)Phase 3Hepatitis A VaccineVaccinesSep 2027
NCT06058416Healive (hepatitis A vaccine (human diploid cell), inactivated)Phase 4Hepatitis AInfectious diseaseMar 2028

From the company's SEC filings

Cash and short-term investments of $6.0bn on 2025-12-31; operating cash outflow about $514m a year; runway about 140 months at that burn, to Aug 2037; 6 of 6 coming phase 2-3 readouts fall inside that runway

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

EV71 (1) CA16 (1)

Companies with the same targets

–

Companies built like this

Liaoning Chengda Biotechnology MAXVAX Biotechnology Limited Liability Company CanSino Biologics Xiamen Innovax Biotech Anhui Zhifei Longcom Biologic Pharmacy

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.